BioCryst Pharmaceuticals, Inc. , a biotechnology company, discovers novel, oral, and small-molecule medicines.
Biocryst Pharmaceuticals stock last closed at $9.33, down 2.41% from the previous day, and has increased 19.16% in one year. It has overperformed other stocks in the Biotechnology industry by 0.59 percentage points. Biocryst Pharmaceuticals stock is currently +55.5% from its 52-week low of $6.00, and -17.51% from its 52-week high of $11.31.
As of Mar 27, 2026, there are 250.8M shares of BCRX outstanding. The market value of BCRX is $2.34B. In the past 24 hours, 4.33M BCRX shares were traded.
How to Buy Biocryst Pharmaceuticals Stock
Wondering how to invest in Biocryst Pharmaceuticals stock? Here's how.
Choose where to buy Biocryst Pharmaceuticals stock: You need to choose an online brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you decide where to buy Biocryst Pharmaceuticals stock.
Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit money your brokerage account: Pick your payment method and add your information.
Evaluate Biocryst Pharmaceuticals stock: The Biocryst Pharmaceuticals ticker symbol is BCRX. Is Biocryst Pharmaceuticals stock a good investment? Should you buy shares of BCRX? How do BCRX's underlying business fundamentals look? Do top analysts think Biocryst Pharmaceuticals is a good buy? Why has BCRX's stock price moved recently? (Hint: Our stock research website can help you decide if BCRX is a good stock to buy).
Execute your BCRX purchase: Decide if you will purchase BCRX shares at the current market price or use a limit order to buy BCRX stock at a given price.
Get updates on your BCRX investment: Create a watchlist to monitor your position in Biocryst Pharmaceuticals stock.
Step 1: Choose where to buy Biocryst Pharmaceuticals stock
You need a brokerage account to access the NASDAQ market and buy BCRX shares.
A brokerage account enables you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
In our opinion, eToro is the best online stock brokerage. eToro gives you:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to world financial markets: From Tech to Utilities, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro has a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've picked the best brokerage, you need to fill out some personal information so you can buy BCRX today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Biocryst Pharmaceuticals stock
After you have selected the best place to buy Biocryst Pharmaceuticals stock, it's critical to research their stock before you buy, so you actually wrap your head around the risk as well as the opportunity.
Biocryst Pharmaceuticals stock at a glance
BCRX Price
$9.33
1w %
-3.81%
1y %
19.16%
5y %
-4.06%
P/E
7.4x
P/B
-19.64x
P/S
2.24x
PEG
N/A
Revenue
$874.84M
Earnings
$263.86M
Fore. Rev. Growth
0.66%
Fore. Earn. Growth
-23.25%
Market Cap
$2.34B
Next Earnings
N/A
Next Dividend
N/A
Biocryst Pharmaceuticals Due Diligence Score
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis quickly.
BCRX's operating cash flow of $347.37M allows it to safely service it's debt of $477.33M.
BCRX profit margin has gone up from -19.7% to 30.2% in the past year.
There are more short-term assets than short-term liabilities on the BCRX balance sheet.
Cons:
There are more long-term liabilities than short-term assets on the BCRX balance sheet.
Total BCRX debt is still negative.
BCRX debt to equity ratio of -5.32 is negative.
BCRX earnings of $346.26M is not sufficient to cover its interest payments.
Is it a good time to buy Biocryst Pharmaceuticals stock, according to analysts?
Out of 7 Wall Street analysts who give ratings on BCRX, the consensus analyst rating on Biocryst Pharmaceuticals is a Buy
It's important to note that analyst forecasts are not recommendations, nor are they investment advice.
Latest BCRX Analyst Upgrades/Downgrades
Stacy Ku, a bottom 37% analyst from TD Cowen reinstates BCRX with a strong buy rating and announces their BCRX price target of $30.00, on Oct 15, 2025.
Steven Seedhouse, a top 12% analyst from Cantor Fitzgerald maintains BCRX with a strong buy rating and raises their BCRX price target from $24.00 to $26.00, on Oct 15, 2025.
Cantor Fitzgerald's Steven Seedhouse raised their price target on Biocryst Pharmaceuticals (NASDAQ: BCRX) by 8.3% from $24 to $26 on 2025/10/15. The analyst maintained their Strong Buy rating on the stock.
Although BioCryst Pharmaceuticals will report its Q3 2025 earnings on 2025/11/03, that was not the catalyst for Seedhouse's price target hike.
Rather, the analyst cited for their move the "terrific value" of the company proposed $700MM (Enterprise Value) acquisition of Astria Therapeutics, even before accounting for essentially total SG&A synergy.
The deal will allow BioCryst Pharmaceuticals to protect and extend its core HAE commercial leadership position through to navenibart's loss of exclusivity in 2042, the analyst detailed.
Last year, BCRX revenue was $874.84M. During the last five year, BCRX's revenue has grown by 117.89% per year. This was faster than the Biotechnology industry average of 29.01%.
No, Biocryst Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other investors have to say about BCRX?
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your BCRX purchase
You have two primary order types:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are mostly sufficient.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at an exact price, use a limit order.
Hit the Open Trade button and your broker will execute your order.
If you require more help investing in stocks on eToro, watch the how to video below:
How much does it cost to buy one Biocryst Pharmaceuticals share?
As of Mar 27, 2026, it costs $9.33 to buy one share of Biocryst Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $4, you can buy 0.429 shares of BCRX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.